drugset / Trial / NCT04120233
MW151-101: First-in-human Study of MW151
Phase 1
Completed
40 enrolled
Linda Van Eldik
Duke Clinical Research Institute · collabNational Institute on Aging (NIA) · collab
RandomizedSequentialSingle-blindOther
Summary
MW01-2-151SRM (=MW151), a small molecule, is being developed for the treatment of cognitive disorders. The development program is based on nonclinical evidence that MW151 improves neurocognitive outcomes in animal models of radiation-induced cognitive impairment, Alzheimer's disease, and other central nervous system (CNS) disorders. The present study will provide safety and pharmacokinetic (PK) information on single ascending doses to support decisions for continued clinical development.
Timeline
- Start
- 2019-10-22
- Primary completion
- 2021-09-16
- Completion
- 2021-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MINOZAC FREE BASE | Small molecule | 10 mg | Oral |
| Subject | MINOZAC FREE BASE | Small molecule | 20 mg | Oral |
| Subject | MINOZAC FREE BASE | Small molecule | 40 mg | Oral |
| Subject | MINOZAC FREE BASE | Small molecule | 80 mg | Oral |
| Subject | MINOZAC FREE BASE | Small molecule | 160 mg | Oral |